Abstract
MicroRNAs (miRNA), small noncoding RNA molecules, are endogenous regulators of gene expression that have been implicated in the pathogenesis of various diseases such as cancer and arthritis. The aim of this study was to explore the biological function of microRNA-16-5p (miR-16-5p) and the molecular mechanism in osteoarthritis (OA). MiRNA targets were identified using bioinformatics. Using real-time PCR, the expression of miR-16-5p and SMAD3 in cartilage specimens was determined in 10 patients with knee OA and in 10 traumatic amputees (control). Functional analysis of miR-16-5p in chondrocytes was performed at both mRNA and protein levels after miRNA transfection. A luciferase reporter assay was used to verify interaction between miRNA and target mRNA. Expression of miR-16-5p was significantly higher in OA cartilages than in healthy cartilages. The data from the reporter assay and western blots indicated that miR-16- 5p regulated SMAD3 expression. Functional analysis showed that miR-16-5p could reduce expression of type IIcollagen and aggrecan while inducing expression of matrix metalloproteinases and ADAMTS; however, miR-16-5p inhibition could reverse these effects. Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA.
Keywords: miR-16-5p, SMAD3, osteoarthritis, chondrocytes.
Current Pharmaceutical Design
Title:MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes
Volume: 21 Issue: 35
Author(s): Lisong Li, Jie Jia, Xianzhe Liu, Shuhua Yang, Shunan Ye, Wen Yang and Yukun Zhang
Affiliation:
Keywords: miR-16-5p, SMAD3, osteoarthritis, chondrocytes.
Abstract: MicroRNAs (miRNA), small noncoding RNA molecules, are endogenous regulators of gene expression that have been implicated in the pathogenesis of various diseases such as cancer and arthritis. The aim of this study was to explore the biological function of microRNA-16-5p (miR-16-5p) and the molecular mechanism in osteoarthritis (OA). MiRNA targets were identified using bioinformatics. Using real-time PCR, the expression of miR-16-5p and SMAD3 in cartilage specimens was determined in 10 patients with knee OA and in 10 traumatic amputees (control). Functional analysis of miR-16-5p in chondrocytes was performed at both mRNA and protein levels after miRNA transfection. A luciferase reporter assay was used to verify interaction between miRNA and target mRNA. Expression of miR-16-5p was significantly higher in OA cartilages than in healthy cartilages. The data from the reporter assay and western blots indicated that miR-16- 5p regulated SMAD3 expression. Functional analysis showed that miR-16-5p could reduce expression of type IIcollagen and aggrecan while inducing expression of matrix metalloproteinases and ADAMTS; however, miR-16-5p inhibition could reverse these effects. Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA.
Export Options
About this article
Cite this article as:
Li Lisong, Jia Jie, Liu Xianzhe, Yang Shuhua, Ye Shunan, Yang Wen and Zhang Yukun, MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150909094712
DOI https://dx.doi.org/10.2174/1381612821666150909094712 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways
Current Cancer Drug Targets A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Recent Patents on Anti-Cancer Drug Discovery Inhibition of Lysozyme by Taurine Dibromamine
Protein & Peptide Letters Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Letters in Organic Chemistry Herpesvirus / Retrovirus Chimeric Vectors
Current Gene Therapy Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin
Current Medicinal Chemistry - Anti-Cancer Agents Natural Polymers Based Hydrogels for Cell Culture Applications
Current Medicinal Chemistry The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets